Biochemical control of bone loss and stone-forming propensity by potassium-calcium citrate after bariatric surgery

In RYGB patients, PCC supplementation inhibited bone resorption by providing bioavailable calcium, reduced the urinary saturation of uric acid, and increased the inhibitor activity against calcium oxalate agglomeration by providing alkali that increased urinary pH and citrate.